Glucose control of glucagon secretion—‘There’s a brand-new gimmick every year’

ERIK GYLFE
Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden

ABSTRACT
Glucagon from the pancreatic α-cells is a major blood glucose-regulating hormone whose most important role is to prevent hypoglycaemia that can be life-threatening due to the brain’s strong dependence on glucose as energy source. Lack of blood glucose-lowering insulin after malfunction or autoimmune destruction of the pancreatic β-cells is the recognized cause of diabetes, but recent evidence indicates that diabetic hyperglycaemia would not develop unless lack of insulin was accompanied by hypersecretion of glucagon. Glucagon release has therefore become an increasingly important target in diabetes management. Despite decades of research, an understanding of how glucagon secretion is regulated remains elusive, and fundamentally different mechanisms continue to be proposed. The autonomous nervous system is an important determinant of glucagon release, but it is clear that secretion is also directly regulated within the pancreatic islets. The present review focuses on pancreatic islet mechanisms involved in glucagon regulation of glucagon release. It will be argued that α-cell-intrinsic processes are most important for regulation of glucagon release during recovery from hypoglycaemia and that paracrine inhibition by somatostatin from the δ-cells shapes pulsatile glucagon release in hyperglycaemia. The electrically coupled β-cells ultimately determine islet hormone pulsatility by releasing synchronizing factors that affect the α- and δ-cells.

Introduction
After Paul Langerhans’s discovery of the pancreatic islets in 1869 (1), Diamare found in 1899 that they contain two types of cells (2), which Lane in 1907 designated as α- and β-cells (3) (later also A and B cells). In 1915 Homans predicted that the B cells are the origin of ‘an internal secretion vital to the utilization of dextrose’ (4), and the glucose-lowering hormone, insulin, was discovered by Banting and Best in 1921 (5). In 1923 Murlin et al. observed that pancreatic insulin extracts sometimes were contaminated with a hyperglycaemic factor (6) that was named glucagon (7), whose production was eventually linked to the α-cells by Sutherland and De Duve in 1948 (8). Claes Hellerström, who is honoured in the current issue of this journal, made significant contributions in the glucagon field in his early scientific career. Together with his mentor Bo Hellman, Hellerström invented a silver impregnation technique that revealed A cell heterogeneity (9). The silver-positive and -negative A cells were named A1 and A2, respectively. They also provided indirect evidence that glucagon originates from the A2 cells by showing that they undergo pronounced nuclear atrophy after glucagon injections (10). Hellerström later pioneered studies of glucagon biosynthesis in guinea pig islets (11) as well as studies of metabolism (oxygen consumption) in A cell-enriched islets from streptozotocin-diabetic guinea pigs (12). Hellman and Lernmark showed that the α1 or A1 cells, which later proved to be identical to the D cells defined by Bloom in 1931 (13), secrete a factor that inhibits insulin secretion (14). This D cell (δ-cell) factor was later identified as somatostatin (15). There is still some confusion with regard to the use of the Greek or Latin designations, but the glucagon-producing cells are nowadays mostly referred to as α-cells and those secreting insulin and somatostatin as β- and δ-cells, respectively, which is the nomenclature subsequently used in this review.

With the discovery of insulin, life-saving treatment of diabetic patients rapidly became possible (16). It is consequently not surprising that most research has been focused on insulin and its actions in the search for improved strategies for optimizing blood glucose control and preventing secondary diabetes complications. Although it has become increasingly clear that hypersecretion of glucagon contributes to hyperglycaemia in diabetes (see (17) for review), it may have surprised many when the Unger group provided evidence that lack of insulin does not lead to diabetes in mice if the blood glucose-elevating effect of glucagon is prevented (18,19). However, disruption of glucagon action/secretion did not improve glucose tolerance in diabetic mice in another study (20).

Whereas diabetic hyperglycaemia may persist undetected for long periods of time, severe hypoglycaemia is acutely life-threatening due to the brain’s strong dependence on glucose as energy source. Glucagon is the major glucose counterregulatory hormone, and its physiologically most important role is to prevent hypoglycaemia. Glucagon secretion is consequently stimulated when the blood sugar concentration falls below the resting level. Unfortunately, also this
mechanism is compromised in diabetes (21), implying deteriorated recovery from dangerous hypoglycaemia that may occur accidentally in patients subjected to aggressive glucose-lowering treatment to reduce diabetes complications. Being essential for survival and well-being, the release of insulin and glucagon is controlled by multiple direct and indirect mechanisms. The blood glucose concentration is e.g. monitored by glucose-sensing cells in the portal vein area and in different regions of the brain, resulting in parasympathetic stimulation of insulin release in hyperglycaemia and glucagon release in hypoglycaemia, as well as sympathetic inhibition of insulin and stimulation of glucagon secretion in hypoglycaemia (22,23). However, the contribution of neural influence may differ between species since human islets are less innervated than rodent islets (24). Moreover, it is clear that glucose control of insulin and glucagon secretion persists in the perfused pancreas and isolated pancreatic islets. The subsequent focus will be on the glucose regulation of glucagon release that occurs within the pancreatic islets.

Already 30 years ago there was a unifying theory how the β-cells recognize glucose and the subsequent signalling that triggers release of insulin (25). The major aspects of the so-called consensus hypothesis are still valid and imply that glucose is rapidly taken up by the β-cells and metabolized to generate ATP. The resulting increase of the ATP/ADP ratio closes ATP-sensitive K⁺ (KATP) channels to depolarize the β-cell and open voltage-dependent L-type Ca²⁺ channels. Subsequent influx of Ca²⁺ raises the cytoplasmic Ca²⁺ concentration ([Ca²⁺]), which is the most important trigger of insulin release. This model consequently implies that the β-cells have an intrinsic capacity to sense glucose and release insulin as required, but [Ca²⁺]-triggered secretion can also be enhanced or reduced by increase or decrease of cAMP, as well as by modulation of protein kinase C and the protein phosphatase calcineurin, mediated by paracrine effects of α-cell glucagon, δ-cell somatostatin and neurotransmitters like acetylcholine and noradrenaline (26,27).

The understanding of how glucose regulates glucagon secretion from the α-cells has progressed much more slowly, and it is remarkable that fundamentally different mechanisms continue to be proposed. Although Ca²⁺ and cAMP are generally believed to have similar secretion-triggering and -amplifying functions for glucagon as for insulin secretion (28–33), recent data indicate that glucagon release may sometimes be controlled independently of [Ca²⁺] (34–36). Lack of paracrine inhibition of the α-cells is often considered to underlie glucagon hypersecretion in diabetic hyperglycaemia, and paracrine factors have also been implicated in glucose control of glucagon secretion in hypoglycaemia. However, the spectrum of putative paracrine factors released from adjacent islet cells clearly differs under hypo- and hyperglycaemia due to specific glucose sensitivities of the different islet cell types (Figure 1). This review will therefore consider how glucose controls glucagon secretion by α-cell interactions with other islet cells as well as by α-cell-intrinsic mechanisms that contribute differently depending on the prevailing glucose concentration (Figure 2). The present contribution extends and updates a previous review with similar focus on glucose (37)

**Figure 1.** Dose–response relationships for glucose-regulated secretion of glucagon, insulin, and somatostatin. Batches of mouse islets were incubated for 60 min with glucose concentrations ranging from 0 to 30 mM. Glucagon secretion is expressed per cent of that stimulated by absence of glucose, whereas insulin and somatostatin secretion are expressed per cent of that stimulated by 30 mM glucose. Mean values ± SEM for eight experiments. The illustration is essentially based on data, from Vieira et al. 2007 (40), combined with data at 25 and 30 mM glucose that were not included in the original publication. Glucagon secretion at >20 mM glucose exceeds that stimulated by the absence of sugar.

**Figure 2.** Models for local glucose regulation of glucagon secretion within pancreatic islets. Only the β-cells are electrically coupled by gap junctions (GJ). When stimulated by glucose they release insulin, γ-aminobutyric acid (GABA), Zn²⁺, or γ-hydroxybutyric acid (GHB), which have been implicated to mediate inhibition of glucagon secretion from the α-cells. β-Cell-mediated inhibition of the α-cells could also involve juxtacrine ephrin-A-EphA forward signalling. The δ-cells are stimulated by glucose and probably by insulin to release somatostatin that inhibits glucagon release from the α-cells. In addition, glucose has direct inhibitory effects on glucagon release by β-cell-intrinsic mechanisms. but is more limited than another review (38) with regard to other modulators of glucagon release.

**Autocrine amplification of glucagon release**

Mouse and human pancreatic islets exposed to hypoglycaemic conditions increase their release of glucagon with maximal effect in the complete absence of sugar (39–41), although there should be less energy available to fuel α-cell secretion under such conditions. Positive feedback has been
proposed to potentiate secretion in this situation and to explain how relatively modest changes in blood glucose can guarantee appropriate regulation of glucagon release (42). Indeed, glucagon has been found to amplify its own secretion by raising \( \alpha \)-cell cAMP (32,33), and glutamate co-released with glucagon can promote secretion by raising \( \text{Ca}^{2+} \) after autocrine activation of AMPA/kainate receptors (42).

**Paracrine control of glucagon release**

*Inhibition by \( \beta \)-cell factors*

Insulin released from the \( \beta \)-cells was first proposed (43) and is still considered as a putative mediator of glucose-inhibited glucagon secretion (18,44). Insulin may activate ATP-sensitive K\(^+\) (\( K_{ATP} \)) channels to hyperpolarize the \( \alpha \)-cells and close voltage-dependent \( \text{Ca}^{2+} \) channels (45), increase the expression of inhibitory \( \gamma \)-aminobutyric acid (GABA) \( \alpha \) receptors (see below) (46), or induce cAMP degradation after activation of phosphodiesterase 3B (44). Other studies proposed that \( \text{Zn}^{2+} \) co-released with insulin mediates the inhibition (47,48), which involves \( K_{ATP} \) channel activation and hyperpolarization of the \( \alpha \)-cells (45,49). Release of ATP from the secretory granules has also been implicated in paracrine inhibition of \( \alpha \)-cell \( \text{Ca}^{2+} \) signalling and glucagon secretion from mouse islets (50). Despite an anticipated \( \text{Ca}^{2+} \)-elevating effect of ATP, this inhibition of secretion was somehow proposed to involve activation of P2Y1 purinoceptors. This finding is contradicted by the observation in rat islets that blockade of this receptor inhibits rather than stimulates glucagon release (51). Other putative inhibitory \( \beta \)-cell-derived messengers are GABA (52) and its metabolite \( \gamma \)-hydroxybutyric acid (GHB) (53). GABA, which inhibits glucagon release by activating a hyperpolarizing \( \text{Cl}^- \) influx in \( \alpha \)-cells (52), is present in \( \beta \)-cell synaptic-like microvesicles and insulin-containing granules that undergo exocytosis in response to glucose stimulation (54,55). However, there is also non-vesicular GABA (55,56), and total release was actually reported to be inhibited by glucose (56). GHB, whose release by an unknown mechanism is stimulated by glucose, acts on putative inhibitory receptors on the \( \alpha \)-cells (53).

Most evidence that paracrine \( \beta \)-cell factors mediate glucose inhibition of glucagon release comes from experiments comparing hypoglycaemic (<3 mM) and hyperglycaemic (>8 mM) concentrations of glucose. However, maximal inhibition of glucagon release from mouse and human islets is reached already at 5–7 mM glucose (39–41), which corresponds to normal glycaemia in these species (Figure 1). A general problem with the idea that glucose-induced release of insulin and factors co-released with insulin mediate inhibition of glucagon secretion is that insulin release from mouse islets is only stimulated by glucose concentrations higher than 5–7 mM (Figure 1) (39–41). Although the human threshold for insulin secretion is somewhat lower (41), glucagon release is regulated by glucose also below this threshold. Exogenously administered insulin has nevertheless been found to inhibit glucagon secretion from human islets exposed to 1 mM glucose (41), but an insulin receptor antagonist had no effect on glucagon secretion from mouse islets exposed to 3 mM glucose (36). If basal insulin release affects glucagon secretion under hypoglycaemic conditions its role may be permissive rather than regulatory. It cannot be excluded that release of a putative inhibitory \( \beta \)-cell factor is controlled by lower glucose concentrations than those regulating insulin secretion. However, evidence is currently lacking that \( \beta \)-cell exocytosis of different types of vesicles shows separate glucose dependencies (54). The possibility remains that non-vesicular release of inhibitory factors may be controlled by glucose concentrations lower than those triggering exocytosis. In the case of GABA, such control does not seem to mediate inhibition of glucagon secretion. As mentioned above, total GABA release is inhibited rather than stimulated by glucose (56). While 5 mM glucose was found to stimulate GHB release from human islets (53), it remains to be established if secretion is differently regulated than that of insulin, since this glucose concentration is above the threshold for insulin secretion from human islets.

There are obviously reasons to doubt that inhibitory \( \beta \)-cell factors mediate glucose regulation of glucagon in hypoglycaemia. However, the involvement of these factors in direct control of glucagon secretion in hyperglycaemia is also questionable. Studies of human (57) and mouse (58) islets exposed to 20 mM glucose have revealed that insulin and glucagon are released in pulses that are synchronized in opposite phase (Figure 3). Such synchronization apparently explains why the circulating concentrations of the two hormones also

![Figure 3](https://example.com/image.png)
oscillate in opposite phase in healthy human subjects (59). As mentioned above, Ca²⁺ oscillations are generally assumed to be the final trigger of both insulin and glucagon secretion, and pulsatile insulin release is indeed paralleled by synchronous β-cell oscillations of [Ca²⁺], (60). To mirror the secretory pattern of both hormones, [Ca²⁺], oscillations are consequently expected to synchronize in opposite phase between α- and β-cells within islets. Therefore, it was utterly surprising to find that the [Ca²⁺], oscillations of α- and β-cells tend to synchronize in the same phase in islets exposed to 20 mM glucose (36). Such synchronization seems to exclude that insulin, Zn²⁺ (45,49), or GABA (52) should mediate glucose inhibition of glucagon release by hyperpolarizing the α-cells to lower [Ca²⁺]. A remaining possibility is that insulin instead acts by lowering cAMP (44), but another study did not find any effect of insulin receptor blockade on glucagon secretion at 20 mM glucose (36). Moreover, a putative action of GHB (53) remains to be explored.

Stimulation by β-cell factors

A paracrine β-cell influence on the α-cells is necessarily not only inhibitory. The dose–response relationship for glucose-regulated glucagon release from mouse and human islets does not show monotonous inhibition. Maximal inhibition of glucagon release is obtained by raising glucose to 5–7 mM, and at higher concentrations the inhibition is gradually reduced (39–41). Concentrations above 20 mM even stimulate glucagon secretion from mouse islets (39). This U-shaped glucose concentration dependence indicates involvement of both inhibitory and stimulatory effects of glucose (Figure 1). The stimulatory component has been attributed to insulin based on the observation that this hormone stimulates rather than inhibits glucagon release from human islets exposed to 6 mM glucose (41), but studies with a receptor antagonist indicated that insulin is inhibitory (44) or lacks effect (36) on glucagon release under hyperglycaemic conditions. ATP from the insulin secretory granules and adenosine formed by extracellular ATP degradation are other putative amplifiers of glucagon secretion. The well-established stimulatory effect of adenosine is mediated by cAMP-elevating A₂ receptors (50,61,62), whereas direct ATP actions on Ca²⁺-elevating P₂Y1 purinoceptors have been claimed either to stimulate (51) or to inhibit (50) glucagon release. A particularly interesting aspect of P₂Y1 purinoceptor signalling is that it can mediate synchronization of the insulin secretion-generating [Ca²⁺], oscillations among dispersed β-cells (63) and pancreatic islets (64) that lack physical contact. ATP released from the electrically coupled β-cells within an islet and acting on P₂Y1 purinoceptors on non-coupled α-cells may well explain the above-mentioned paradoxical synchronization of Ca²⁺ oscillations between β- and α-cells (36). It seems possible that more than one inhibitory mechanism may be required to suppress glucagon secretion under hyperglycaemic conditions. General conclusions based on commonly used experimental conditions may consequently overemphasize paracrine β-cell factors in the direct control of glucagon release in general and during hypoglycaemia in particular. It is therefore reassuring that some recent studies focus on regulation of glucagon secretion in recovery from hypoglycaemia by studying the 0–7 mM glucose range (31,39,41,65).

Inhibition by somatostatin from δ-cells

Somatostatin from the δ-cells is a potent inhibitor of both insulin and glucagon release and was early proposed as a paracrine regulator of glucagon release (66) mediating the inhibitory effect of hyperglycaemia (67). Preferential inhibition of glucagon release follows from the higher α- than β-cell sensitivity to somatostatin (68), probably reflecting somatostatin receptor (SSTR) subtype differences with SSTR2 dominating in rodent and human α-cells, and SSTR1 and SSTR5 in human and rodent β-cells, respectively (69–71). The closer spatial association between δ- and α-cells than that between δ- and β-cells in mouse islets (72) may also contribute to the preferential effect on glucagon secretion in this species. Somatostatin acts by reducing adenylyl cyclase production of cAMP via the Gαi subunit coupled to the SSTR2 (44) and by de-priming the glucagon secretory granules after activation of the serine/threonine protein phosphatase calcineurin (73). Compared to β-cell factors, a conceptual advantage of somatostatin-mediated glucose inhibition of glucagon release is that it may operate also in hypoglycaemia, since glucose stimulates somatostatin release from mouse and human islets at similar concentrations that inhibit glucagon secretion (Figure 1) (39–41). Indeed, blockade of the α-cell SSTR2 (40), perturbation of Gαi signal transduction by pertussis toxin treatment, or knockout of the somatostatin gene (65) enhances glucagon secretion from mouse islets exposed to 0, 1, or 7 mM glucose. However, these conditions do not prevent glucose elevation from inhibiting glucagon secretion. Pertussis toxin treatment also did not prevent inhibition of glucagon secretion from mouse islets in response to a 1 to 20 mM glucose increase (74), but in another study such treatment eliminated the inhibitory effect of a 1 to 11 mM glucose elevation by increasing secretion at the higher concentration (44). In human islets SSTR2 blockade had no effect on glucagon release at either 1 or 6 mM glucose (41), but in another study SSTR2 blockade prevented glucose inhibition by stimulating glucagon secretion at 11 mM but not at 1 mM glucose (44). On the other hand, pertussis toxin treatment eliminated glucose inhibition of glucagon release from human islets by inhibiting secretion at 1 mM but with no effect at 6 mM glucose (41). Taken together, these studies offer measure support that somatostatin mediates glucose inhibition of glucagon release in the 0–7 mM range, and three studies concluded that the effect of somatostatin is tonic rather than regulatory (40,65,74).

The studies with SSTR2 blockade or pertussis toxin treatment provided conflicting results regarding involvement of somatostatin in glucose inhibition of glucagon release under hyperglycaemic conditions with 11 or 20 mM glucose (44,74). Tolbutamide, which like glucose acts by closing KATP channels to depolarize islet cells, stimulates the release of both insulin (25) and somatostatin (75) and inhibits glucagon release from islets exposed to 1 mM glucose (65). However, tolbutamide becomes stimulatory in pertussis toxin-treated islets, or in
those from somatostatin knockout mice, and is also stimulatory when glucagon release is already inhibited by exposure to 7 mM glucose (65). Together with observations that glucose concentrations in the 0–20 mM range stimulate glucagon release from purified rat and mouse \( \alpha \)-cells (76–78), these data indicate that the direct effect of \( K_{\text{ATP}} \) channel closure in \( \alpha \)-cells is stimulatory (see below) and that this stimulation is counteracted by the simultaneously enhanced release of inhibitory somatostatin. Further evidence for a role of somatostatin in the regulation of glucagon secretion in hyperglycaemia is obtained from the kinetics of secretion. Pulsatile hormone release from human and mouse islets is generated by hyperglycaemia with coinciding pulses of insulin and somatostatin that are synchronized in opposite phase to the glucagon pulses (57,58). This relationship is consistent with the possibility that somatostatin peaks generate the nadirs of pulsatile glucagon release. Since pulsatile glucagon release is paradoxically synchronized in opposite phase to the \( \alpha \)-cell oscillations of [Ca\(^{2+}\)]\(_i\) (discussed above), such a role requires that somatostatin inhibits glucagon release when [Ca\(^{2+}\)]\(_i\) is peaking. This may well be the case since SSTR2 blockade potently amplifies glucagon release from mouse islets exposed to 20 mM glucose without marked effects on the [Ca\(^{2+}\)]\(_i\) oscillations in \( \alpha \)-cells (36). Despite somatostatin’s documented potency as inhibitor of glucagon release (68) and the fact that its secretion increases concentration-dependently up to 30 mM glucose (Figure 1), its paracrine action does not prevent that inhibition of glucagon release from mouse and human islets is gradually diminished in the 7–20 mM range (40,41). The time-average rate of pulsatile glucagon secretion at 20 mM glucose actually represents a rather modest inhibition compared to secretion at 3 mM glucose (57,58).

Juxtacrine control of glucagon release

Cells in direct contact often communicate by interactions between surface-bound ephrin and Eph molecules that function as ligands and receptors, or both, and can mediate bidirectional signalling to control cellular functions (79). Eph molecules are tyrosine kinase receptors activated by ephrin. ‘Forward’ signalling from \( \beta \)-cell ephrinA ligand to \( \beta \)-cell EphA receptors has been found to inhibit insulin release by promoting polymerization of an actin network beneath the plasma membrane, whereas ‘reverse’ signalling from EphA to ephrinA promotes secretion by actin depolymerization (80). Glucose amplification of forward signalling from \( \beta \)-cell ephrinA to \( \alpha \)-cell EphA4 receptors was recently proposed to complement paracrine inhibition of glucagon release (Figure 2) and explain glucagon hypersecretion when \( \beta \)-cells disappear in diabetes (78). The most compelling argument for such ‘juxtacrine’ control of glucagon release is that artificial activation of forward signalling by exposure to IgG-fused ephrinA molecules restores characteristic glucose inhibition of glucagon release from purified \( \alpha \)-cells, which otherwise respond with stimulated secretion (78). The proposed model with juxtacrine \( \beta \)-cell control of glucagon secretion from \( \alpha \)-cells is interesting, but available data are limited and further studies are required to pinpoint whether the effects are regulatory or permissive. Apart from shedding light on the regulation of glucagon release, juxtacrine mechanisms may perhaps help to explain considerable differences in glucose-regulated [Ca\(^{2+}\)]\(_i\), signaling between isolated \( \alpha \)-cells (81) and those located in their natural environment within pancreatic islets (36).

\( \alpha \)-Cell intrinsic glucose control of glucagon release

According to the consensus model for glucose-induced insulin release (see above), metabolism of glucose is essential for \( \beta \)-cell recognition of the sugar as stimulus. Considering that hormone secretion is glucose-regulated also in islet \( \alpha \)- and \( \delta \)-cells and that these cell types originate from a common progenitor (82), it seems likely that glucose might be sensed by similar cellular mechanisms. Indeed, glucose metabolism has a central role in different models of \( \alpha \)-cell-intrinsic glucose regulation of glucagon release. Glucose transport into rodent \( \beta \)-cells is mediated by the high-\( K_m \) GLUT2 (83), which seems tailored for sensing blood glucose in hyperglycaemia. From this point of view it is natural that rodent \( \alpha \)-cells, which are expected preferentially to sense glucose in hypoglycaemia, express the low-\( K_m \) GLUT1 transporter (84,85). However, human \( \beta \)-cells that sense higher concentrations also express the low-\( K_m \) GLUT1 (83), and glucose transport is not rate-limiting for its metabolism since it has been estimated to be 5- to 10-fold higher than glucose utilization in both \( \alpha \)– and \( \beta \)-cells (84,85). The high-\( K_m \) glucokinase, which is the dominating glucose-phosphorylating enzyme, is instead the rate-limiting glucosensor in \( \beta \)-cells (86) and may have this function also in \( \alpha \)-cells with similar glucokinase activity (85). There is also some \( \alpha \)-cell expression of low-\( K_m \) hexokinase, but its significance is unclear, since this enzyme is saturated already by 1 mM glucose (85). The subsequent glycolytic flux is comparable in \( \beta \)– and \( \alpha \)-cells (84), but glucose oxidation is considerably lower in \( \alpha \)-cells (87,88) and the oxidative phosphorylation less efficient due to high expression of uncoupling protein 2. These differences are reflected by much smaller glucose-induced changes of ATP (36,47,89), FAD (90), and NAD(P)H (91) in \( \alpha \)- and \( \beta \)-cells. Glucose metabolism is nevertheless essential since a non-metabolizable glucose transport analogue has no effect, whereas glucokinase activation mimics glucose inhibition of glucagon release (65). If glucose metabolism in \( \alpha \)- and \( \beta \)-cells controls glucagon and insulin release in hypo- and hyperglycaemia, respectively, it might be reflected by a relatively left-shifted dependence of metabolism on the glucose concentration in the \( \alpha \)-cell. This seems to be the case since a 1 to 5 mM glucose elevation causes comparable ATP elevation in \( \alpha \)– and \( \beta \)-cells, whereas the \( \beta \)-cell response is much greater after further elevation to 20 mM (36).

There are significant differences in the electrophysiology between \( \beta \)- and \( \alpha \)-cells. In accordance with the secretory patterns the \( \beta \)-cells become electrically active and show [Ca\(^{2+}\)]\(_i\) oscillations at high glucose, whereas the \( \alpha \)-cells are active in the absence of the sugar. Glucose-induced closure of the \( K_{\text{ATP}} \) channels depolarizes the \( \beta \)-cells to open L-type Ca\(^{2+}\) channels that show half-maximal activation at \(-19 \text{mV}\), and this Ca\(^{2+}\) permeability dominates the upstroke of the action potentials in the \( \beta \)-cell (25). It is more complex in \( \alpha \)-cells with T-type
Ca\(^{2+}\) channels that activate at potentials as low as –60 mV and tetrodotoxin (TTX)-sensitive Na\(^+\) channels that open at potentials more positive than –30 mV (28, 29). There are also L-type and perhaps N-type Ca\(^{2+}\) channels in \(\alpha\)-cells (30), although studies with more specific inhibitors indicated that the latter channels might be of P/Q-type (31). Whereas Ca\(^{2+}\) influx through the L-type channels triggers insulin release from \(\beta\)-cells, the relationship between Ca\(^{2+}\) influx into \(\alpha\)-cells and glucagon release is more complicated. In rodent \(\alpha\)-cells L-type channels dominate (80%) and mediate most Ca\(^{2+}\) influx, but their blockade has little effect on secretion. Conversely, blocking the non-L-type channels (20%) has modest effects on [Ca\(^{2+}\)], but inhibits secretion to a similar extent as glucose elevation from 1 mM to 6 or 7 mM (30, 31, 92). The greater importance of the non-L-type channels is attributed to their close association with the glucagon-secretory granules (31, 93). In the presence of adrenaline, which depolarizes \(\alpha\)-cells, mobilizes Ca\(^{2+}\) from the endoplasmic reticulum (ER) (81, 94), and elevates cAMP (33), entry of extracellular Ca\(^{2+}\) through the L-type channels triggers exocytosis of glucagon granules that do not co-localize with these channels (31, 95). In human \(\alpha\)-cells P/Q-type channels dominate over L-type channels (70%/20% of the integrated Ca\(^{2+}\) current) and account for most of the exocytosis, although they open very briefly and only mediate a fraction of the Ca\(^{2+}\) entry (96). The fact that glucose inhibition of glucagon release is associated with a rather modest reduction of [Ca\(^{2+}\)]\(_i\) signalling (36, 81, 91, 97, 98) is consistent with the idea that Ca\(^{2+}\) channels close to the glucagon granules are most important. The background of additional Ca\(^{2+}\) entry may perhaps explain why glucose inhibition of glucagon release is far from complete and has a much lower dynamic range than glucose stimulation of insulin release (39–41).

**K\(_{ATP}\) channel-dependent glucose inhibition of glucagon release**

According to the consensus hypothesis for glucose-stimulated insulin release, ATP acts by blocking K\(_{ATP}\) channels to depolarize the \(\beta\)-cell (see above). The most cited model for \(\alpha\)-cell intrinsic regulation assumes the same sequence of events, meaning that glucose inhibits glucagon release by depolarizing the \(\alpha\)-cells (31, 41, 93, 99–101). The model is somewhat counterintuitive since it nevertheless incorporates the general acceptance that depolarization-induced influx of Ca\(^{2+}\) into the \(\alpha\)-cells triggers glucagon secretion. The background to this riddle is that the \(\alpha\)-cell K\(_{ATP}\) channel activity is almost maximally inhibited even in the absence of glucose (41) and that triggering of glucagon secretion by activation of high-threshold P/Q Ca\(^{2+}\) channels requires opening of low-threshold T-type Ca\(^{2+}\) and Na\(^+\) channels (28, 91). ATP produced in response to glucose elevation closes the remaining K\(_{ATP}\) channels to depolarize the \(\alpha\)-cells slightly and inactivate the low-threshold T-type Ca\(^{2+}\) and Na\(^+\) channels. In this situation the action potential amplitude is reduced and fails to activate secretion-triggering Ca\(^{2+}\) influx through the P/Q channels despite [Ca\(^{2+}\)]\(_i\) elevation by activated L-channels (Figure 4). An implication of the model is that the action potentials that underlie glucagon secretion can only be generated in a narrow membrane potential window, sufficiently depolarized to activate the T-type Ca\(^{2+}\) channels and at the same time sufficiently hyperpolarized to prevent their inactivation as well as that of the TTX-sensitive Na\(^+\) channels (92). The presence of a narrow membrane potential window is supported by observations that slight depolarization by elevation of the K\(^+\) concentration mimics the inhibitory effect of glucose (100) and slight hyperpolarization with low concentrations of K\(_{ATP}\) channel-activating diazoxide can reverse glucose inhibition of glucagon secretion from batch-incubated islets (92, 99), but such reversal could not be reproduced when measuring glucagon secretion from perfused islets (65). The observation that depolarization by complete K\(_{ATP}\) channel closure with tolbutamide inhibits glucagon release has also been taken to support the model (31, 41). However, another study argued that increased release of somatostatin from the \(\delta\)-cells mediates this inhibition, since tolbutamide strongly stimulated glucagon release from somatostatin knockout islets (65). The unexpected observation in normal mouse islets that a high concentration of tolbutamide enhances glucagon release, which has been inhibited by presence of 7 mM glucose, may
reflect a direct tolbutamide stimulation of the \( \alpha \)-cells that overwhelms indirect inhibition by somatostatin (65).

If the K\(_{\text{ATP}}\) channels are central for intrinsic \( \alpha \)-cell recognition of glucose, channel knockout is expected to interfere with glucose regulation of glucagon release. Available data are conflicting also on this point. Whereas some studies found that the inhibitory effect of glucose is lost by K\(_{\text{ATP}}\) channel knockout (100,102), it was attenuated or essentially retained in other studies (65,103,104), and glucose inhibition of glucagon release was amplified when static inhibition of glucagon release by somatostatin was prevented by treating the K\(_{\text{ATP}}\) channel knockout islets with pertussis toxin (65). There are also divergent opinions on the effect of glucose after chemical knockout of the K\(_{\text{ATP}}\) channels by exposure to high concentrations of tolbutamide, which prevented glucose inhibition of glucagon release in one study (92) but not in another two (40,91). At high concentrations of diazoxide, which maximally open the K\(_{\text{ATP}}\) channels to hyperpolarize the \( \alpha \)-cells and inhibit glucagon release, glucose can still inhibit secretion further (39,65).

There are very different estimates of the K\(_{\text{ATP}}\) channel expression in \( \alpha \)-cells. In situ hybridization data indicated higher channel density than in \( \beta \)-cells (105), whereas expression was 7-fold lower in the \( \alpha \)-cells based on binding of the fluorescently labelled sulfonylurea glibenclamide (106). In accordance with the latter estimation the whole-cell K\(_{\text{ATP}}\) channel conductance in \( \alpha \)-cells is only about 10% of that in \( \beta \)-cells (28,99). Another difference between the two cell types is that the smaller \( \alpha \)-cells have 100-fold lower membrane conductance (25,28), making the membrane potential more sensitive to small currents. From this point of view it is surprising that exposure to high concentrations of diazoxide to activate all K\(_{\text{ATP}}\) channels and hyperpolarize islet cells eliminates Ca\(^{2+}\) signalling in all \( \beta \)-cells but often fails to completely shut off [Ca\(^{2+}\)]\(_i\) oscillations in \( \alpha \)-cells (36,106). A possible interpretation is that \( \alpha \)-cells have a more positive equilibrium potential for K\(^+\) and that hyperpolarization in response to K\(_{\text{ATP}}\) channel activation is insufficient for complete elimination of the action potentials that originate from membrane potentials of about −55 mV (28,29,93).

A fundamental aspect of the K\(_{\text{ATP}}\) channel hypothesis is that glucose depolarizes the \( \alpha \)-cell, but it is, surprisingly, not settled how glucose affects the membrane potential. Diverging results have been obtained with invasive electrophysiological techniques with both depolarizing (93,100) and hyperpolarizing (28,105,107,108) effects of the sugar. The reason is probably that small stray currents associated with the invasive approach may significantly affect the membrane potential of the small \( \alpha \)-cell with low membrane conductance (28). Inconsistent with the K\(_{\text{ATP}}\) channel hypothesis, membrane potential measurements with dye-based non-invasive technique indicate that glucose hyperpolarizes the \( \alpha \)-cell (81,109).

**Alternative interpretations of data supporting the K\(_{\text{ATP}}\) channel-centred model**

The K\(_{\text{ATP}}\) channel-centred model provides an explanation why slight \( \alpha \)-cell hyperpolarization with low concentrations of diazoxide (92,99) and slight depolarization with small elevations of extracellular K\(^+\) (100) stimulates and inhibits glucagon release, respectively. Although such elegant clarifications of counterintuitive responses may seem convincing, alternative interpretations of these and some other experiments will be discussed. Considering that \( \alpha \)-cells show surprisingly low sensitivity to high concentrations of diazoxide (see above), it seems possible that low concentrations may preferentially act on \( \delta \)-cells to suppress somatostatin release and thus relieve some tonic inhibition of the \( \alpha \)-cells. However, high concentrations of diazoxide likely inhibit glucagon release by hyperpolarizing the \( \alpha \)-cells.

The Na\(^+/K^+\)-pumping ATPase is a major energy consumer in most types of cells and probably also in \( \alpha \)-cells with much lower glucose-induced ATP production than \( \beta \)-cells (discussed above). Reduced Na\(^+/K^+\) pumping may consequently underlie a more positive equilibrium potential for K\(^+\) in \( \alpha \)- than in \( \beta \)-cells as speculated above. Moreover, if the energy utilization for ouabain-sensitive Na\(^+/K^+\) pumping decreases with extra-cellular K\(^+\) elevation up to 14 mM like in squid axon (110), the inhibitory effect of small K\(^+\) elevations on glucagon release may be related to ATP elevation rather than to slight depolarization. This interpretation is consistent with a central role of metabolism in glucose-inhibited glucagon release without necessarily involving K\(_{\text{ATP}}\) channels.

Since the \( \alpha \)-cell K\(_{\text{ATP}}\) channel activity is almost maximally inhibited in the absence of glucose (41), it is difficult to understand how low and high concentrations of tolbutamide can stimulate (92) and inhibit (31,41,92) glucagon release, respectively, if \( \alpha \)-cell K\(_{\text{ATP}}\) channels were the sole target. The K\(_{\text{ATP}}\) channel-centred model offers no explanation for the stimulatory effect of low concentrations of tolbutamide (92). Stimulation is consistent with reports of \( \alpha \)-cell depolarization with [Ca\(^{2+}\)]\(_i\) elevation after K\(_{\text{ATP}}\) channel closure by tolbutamide (40,81,91,111). However, in accordance with the K\(_{\text{ATP}}\) channel-centred model, it was instead the inhibitory effect of tolbutamide on glucagon release that was linked to \( \alpha \)-cell depolarization after K\(_{\text{ATP}}\) channel closure (31,41,92). As discussed above, another study attributed tolbutamide inhibition of glucagon release to stimulated somatostatin secretion, since a high concentration of tolbutamide strongly stimulated glucagon release from somatostatin knockout islets (65).

**Endoplasmic reticulum-dependent glucose inhibition of glucagon release**

In most excitable cells depolarization underlies opening of voltage-dependent Ca\(^{2+}\) influx that triggers a cellular response. From this point of view one might expect that \( \alpha \)-cells depolarize to release glucagon in the absence of glucose and that glucose elevation, contrary to the K\(_{\text{ATP}}\)-centred model, inhibits secretion by \( \alpha \)-cell hyperpolarization. Although opinions differ about the glucose effect on \( \alpha \)-cell membrane potential (see above), hyperpolarization seems to be the most common observation (28,81,105,107–109). The K\(_{\text{ATP}}\) channel-centred model is based on a special ion channel repertoire in \( \alpha \)-cells that differs from that in \( \beta \)-cells, but the involvement of these channels in action potential generation does not
exclude that glucose inhibits glucagon release by hyperpolarizing α-cells. In β-cells, glucose elevation rapidly generates ATP (112) and slight depolarization (113) that coincides with lowering of [Ca^{2+}]_i, (113,114), since ATP not only blocks K_{ATP} channels but also energizes the sarco(endo)plasmic reticulum Ca^{2+} ATPase (SERCA-pump) to sequester Ca^{2+} in the endoplasmic reticulum (ER). It is not until the depolarization is sufficient to open voltage-dependent Ca^{2+} channels that [Ca^{2+}]_i increases (113) to trigger first-phase insulin secretion (115). Similar glucose-induced lowering of [Ca^{2+}]_i by sequestration in the ER was early observed in guinea pig α-cells (116). Adrenaline, which in α-cells acts on α_1- and β-adrenergic receptors to generate inositol (1,4,5)-trisphosphate (IP_3) and cAMP, respectively (94), was found to raise [Ca^{2+}]_i, by mobilizing the glucose-incorporated Ca^{2+} (116). The opposite effects on [Ca^{2+}]_i, were therefore proposed to explain glucose inhibition and adrenaline stimulation of glucagon release (116). While this may seem to make sense, it is unlikely that ER sequestration of Ca^{2+} explains sustained inhibition of glucagon release, since the Ca^{2+} storage capacity is limited. However, the Ca^{2+} filling of the ER controls a store-operated depolarizing current in the plasma membrane that is at least partly carried by Ca^{2+} influx. In β- and α-cells the store-operated current is small, and alone it only causes modest [Ca^{2+}]_i, elevation (81,117,118). Activation of the store-operated current by SERCA inhibition marginally elevates basal [Ca^{2+}]_i, in β-cells (113), whereas α-cells react with a pronounced [Ca^{2+}]_i, elevation involving also voltage-dependent Ca^{2+} entry (81) that stimulates glucagon release (40) and prevents (40) or reduces (100) inhibition by glucose. The likely reason for this difference is that the low membrane conductance of α-cells (28) makes the membrane potential sufficiently sensitive to small depolarizing currents that activate voltage-dependent Ca^{2+} influx. The high sensitivity to small currents is the basis for glucagon release control by store-operated glucose sensing in α-cells (40,81).

The store-operated Ca^{2+} influx in β-cells is inversely related to the Ca^{2+} content of the ER in a graded manner (118). Store-operated control of glucagon release from the α-cells implies that under hypoglycaemia, with little ATP to fuel the SERCA pump, there will be a net release of Ca^{2+} from the ER and activation of the depolarizing store-operated pathway, resulting in voltage-dependent Ca^{2+} influx and glucagon release (Figure 5). During return to normoglycaemia the SERCA pump is gradually more energized to fill the ER with Ca^{2+} and shut off the stimulatory cascade (40,81). Some important differences between α- and β-cells provide arguments in support of the store-operated mechanism. In β-cells 8–20 mM glucose is required to fill the ER (119–121), whereas maximum is reached at 3 mM in the α-cells (81). A similar difference is apparent when comparing the spatio-temporal kinetics of the ER Ca^{2+} sensor STIM1 and the plasma membrane Ca^{2+} channel protein Orai1, which are molecular components of the store-operated pathway. Emptying of ER Ca^{2+} induces STIM1 translocation from the ER to the plasma membrane where it co-clusters with Orai1 to activate the store-operated current in both α- and β-cells, and glucose reverses this process by stimulating re-translocation of STIM1 to the ER in a graded fashion, thus shutting off the store-operated current (122). In β-cells the re-translocation is saturated by 11–20 mM glucose, whereas only 3 mM is required in α-cells. Similar hypoglycaemia-like glucose concentrations consequently control glucagon release and the store-operated pathway in α-cells, whereas quite different concentrations control this pathway in β-cells. The simple idea that glucose inhibition and adrenaline stimulation of glucagon release are explained by stimulation of ER Ca^{2+} sequestration and release, respectively (116), obviously makes sense when the store-operated pathway is taken into account.

**Other α-cell mechanisms for glucose-inhibited glucagon release**

Like in store-operated control of glucagon release, another two hypotheses assume that glucose inhibits secretion by hyperpolarizing the α-cells to shut off voltage-dependent Ca^{2+} entry. Glucose-generated ATP was thus proposed to act by energizing the Na^+/K^+ pump (123). In most types of cells the electrogenic effect of this pump is small (124) but may be significant in α-cells due to the their low membrane content of the ER in a graded manner (119–121), whereas maximum is reached at 3 mM in the α-cells (81). A similar difference is apparent when comparing the spatio-temporal kinetics of the ER Ca^{2+} sensor STIM1 and the plasma membrane Ca^{2+} channel protein Orai1, which are molecular components of the store-operated pathway. Emptying of ER Ca^{2+} induces STIM1 translocation from the ER to the plasma membrane where it co-clusters with Orai1 to activate the store-operated current in both α- and β-cells, and glucose reverses this process by stimulating re-translocation of STIM1 to the ER in a graded fashion, thus shutting off the store-operated current (122). In β-cells the re-translocation is saturated by 11–20 mM glucose, whereas only 3 mM is required in α-cells. Similar hypoglycaemia-like glucose concentrations consequently control glucagon release and the store-operated pathway in α-cells, whereas quite different concentrations control this pathway in β-cells. The simple idea that glucose inhibition and adrenaline stimulation of glucagon release are explained by stimulation of ER Ca^{2+} sequestration and release, respectively (116), obviously makes sense when the store-operated pathway is taken into account.

**Other α-cell mechanisms for glucose-inhibited glucagon release**

Like in store-operated control of glucagon release, another two hypotheses assume that glucose inhibits secretion by hyperpolarizing the α-cells to shut off voltage-dependent Ca^{2+} entry. Glucose-generated ATP was thus proposed to act by energizing the Na^+/K^+ pump (123). In most types of cells the electrogenic effect of this pump is small (124) but may be significant in α-cells due to the their low membrane content of the ER in a graded manner (119–121), whereas maximum is reached at 3 mM in the α-cells (81). A similar difference is apparent when comparing the spatio-temporal kinetics of the ER Ca^{2+} sensor STIM1 and the plasma membrane Ca^{2+} channel protein Orai1, which are molecular components of the store-operated pathway. Emptying of ER Ca^{2+} induces STIM1 translocation from the ER to the plasma membrane where it co-clusters with Orai1 to activate the store-operated current in both α- and β-cells, and glucose reverses this process by stimulating re-translocation of STIM1 to the ER in a graded fashion, thus shutting off the store-operated current (122). In β-cells the re-translocation is saturated by 11–20 mM glucose, whereas only 3 mM is required in α-cells. Similar hypoglycaemia-like glucose concentrations consequently control glucagon release and the store-operated pathway in α-cells, whereas quite different concentrations control this pathway in β-cells. The simple idea that glucose inhibition and adrenaline stimulation of glucagon release are explained by stimulation of ER Ca^{2+} sequestration and release, respectively (116), obviously makes sense when the store-operated pathway is taken into account.
conductance (28). The other hypothesis is based on the observation that glucose elevations inhibiting glucagon secretion cause α-cell swelling (125) and activation of volume-regulated channels, leading to hyperpolarizing Cl− influx (126,127). Another α-cell-intrinsic model is independent of the membrane potential and changes in [Ca2+]i, and focuses on the reduction of AMP that accompanies glucose-induced ATP elevation. The lowering of AMP is assumed to inhibit glucagon release by inactivating AMP-dependent protein kinase (AMPK) (34). Accordingly, activation of AMPK was found to stimulate glucagon release from a clonal α-cell line and mouse pancreatic islets, whereas a dominant-negative form of the kinase blocked the stimulatory effects of low glucose (34). However, knockout of the catalytic α1 sub-unit of AMPK instead sensitized glucagon secretion to the inhibitory action of glucose (128). Currently available data on the involvement of AMPK in glucose-regulated glucagon secretion therefore seem somewhat contradictory.

**Glucose stimulation of glucagon release**

Arguments that glucose inhibition of glucagon release from pancreatic islets depends on para- (76,77) and/or juxtacrine mechanisms (78) were obtained from observations that glucose instead stimulates glucagon release from purified α-cells. A major difference between isolated α-cells and those located within islets is that the latter show consistent [Ca2+]i, activity with oscillations at 1–3 mM glucose (36,77), whereas such activity is observed in less than 10% of isolated α-cells (81). Intra-islet location apparently stimulates the α-cells to induce [Ca2+]i, activity and glucagon release, which is a likely requirement for observing inhibition by glucose. The stimulation may involve autocrine α-cell factors (see above) that act in the narrow intercellular space of islets but whose effect is lost by dilution when studying purified or isolated α-cells. Indeed, increasing glucose in the 1–20 mM range concentration-dependently inhibits [Ca2+]i signalling in isolated α-cells, provided that they are already depolarized (40), which resembles the temporary inhibition of [Ca2+]i, signalling observed in islet-located α-cells after a 3–20 mM glucose elevation (36).

Glucose-induced stimulation of glucagon release from purified α-cells is supposed to mirror that in β-cells with voltage-dependent [Ca2+]i elevation due to depolarization by closure of KATP channels (76), which is opposite to the hyperpolarizing effect of glucose observed in most studies of isolated α-cells (28,81,105,107) or those located in situ within the islets (108,109). Also, glucagon release from pancreatic islets shows a stimulatory glucose component, since maximal inhibition at 5–7 mM is followed by a gradually reduced inhibition at higher concentrations (39–41) that transforms into stimulation above 20 mM of the sugar (Figure 1) (39). Even if closure of

![Figure 6](image-url). Model for paracrine generation of pulsatile glucagon release in hyperglycaemia. The gap junction-coupled β-cells synchronize their Ca2+ oscillations with those of the non-coupled δ-cells and α-cells by releasing factors like ATP. Therefore, the Ca2+ oscillations in the δ-cells will generate pulsatile release of somatostatin in phase with that of insulin. Since somatostatin potently inhibits glucagon release with little effect on α-cell Ca2+, this inhibition will generate pulsatile glucagon release in opposite phase to insulin and somatostatin pulsatility. The lower left graphs show oscillations of the sub-plasma membrane Ca2+ concentration means (dark colour) ± SEM (light colour) of 6 β- and 13 α-cells within a single mouse islet (modified from Li et al. 2015 (36)), as well as an adapted recording from a δ-cell based on preliminary experiments. The graphs showing pulsatile secretion (lower right) are based on data from Hellman et al. 2009 (57).
the $K_{\text{ATP}}$ channels were involved in the stimulatory effect of glucose on glucagon secretion from purified $\alpha$-cells it seems unlikely that this mechanism accounts for stimulation by hyperglycaemic concentrations of the sugar, since the $\alpha$-cell $K_{\text{ATP}}$ channel activity is almost maximally inhibited already in the absence of glucose (41). The question arises whether another process than [Ca$^{2+}$], elevation may explain glucose stimulation. Since glucose inhibition of glucagon release is associated with a rather modest reduction of [Ca$^{2+}$], signalling (36,81,91,97,98), it is possible that secretion shows a greater dependence on amplifying factors and that Ca$^{2+}$ has a more permissive role. Glucose-induced elevation of cAMP in $\alpha$-cells has thus been suggested to underlie glucose stimulation of glucagon release (33), but available data on $\alpha$-cell cAMP are so far limited.

**Conclusions**

A reason why glucose regulation of glucagon secretion is poorly understood is probably that experimental efforts have mostly been focused on finding a single mechanism. It has become increasingly evident that glucose has both inhibitory and stimulatory effects that act directly on the $\alpha$-cell or indirectly via paracrine and/or juxtacrine signalling from other islet cell types. A further complication is that these mechanisms contribute differently depending on the prevailing glucose concentration. Under hypoglycaemic conditions $\alpha$-cell-intrinsic glucose sensing and regulation of glucagon release is probably dominating. Although the two major hypotheses for such sensing seem incompatible in predicting that glucose inhibits glucagon secretion by either depolarizing (31,41,93,99,100) or hyperpolarizing (40,81) the $\alpha$-cell, respectively, a model has been proposed that combines these mechanisms to explain the non-monotonic dependence of glucagon secretion on glucose (129). Most models for $\alpha$-cell-intrinsic glucose regulation of glucagon release focus on Ca$^{2+}$ as the trigger of secretion. However, one should also consider the possibility that Ca$^{2+}$ has a more permissive role and that $\alpha$-cell-intrinsic glucose regulation in terms of inhibition and stimulation is mediated by modulating factors like cAMP and perhaps diacylglycerol. This alternative is particularly attractive considering that glucose only modestly decreases $\alpha$-cell [Ca$^{2+}$], signalling, which likely explains why even maximally inhibited glucagon secretion is only reduced to 25%–45% of maximal release (40,41). In hyperglycaemia paracrine factors become more important for glucose regulation of glucagon release, and the stimulated $\beta$-cells ultimately generate pulsatile secretion of the other islet hormones (Figure 6). Due to gap junction coupling they release insulin together with synchronizing paracrine factors like ATP in a co-ordinated pulsatile fashion to entrain the [Ca$^{2+}$], oscillation of the non-coupled $\delta$- and $\alpha$-cells into a common islet phase. The [Ca$^{2+}$], entrainment of $\beta$- and $\delta$-cells likely explains the coinciding pulses of insulin and somatostatin release. However, the somatostatin pulses inhibit glucagon release despite peaks of $\alpha$-cell [Ca$^{2+}$], thus clarifying how pulsatile glucagon release is synchronized in opposite phase $\alpha$-cell [Ca$^{2+}$], as well as to pulsatile release of the other hormones. Since the stimulatory component of glucose on glucagon secretion increases with sugar concentration, multiple inhibitory processes may be required to ascertain dominating inhibition of glucagon secretion. Glucagon release in diabetes shows two distinct abnormalities—hypersecretion during hyperglycaemia and a failing secretory response to hypoglycaemia. Both abnormalities might be explained if the stimulatory glucose component is somehow amplified to dominate over the inhibitory mechanisms. The molecular events that underlie glucose stimulation of glucagon release should therefore be identified and explored as potential targets in diabetes therapy.

**Disclosure statement**

The author reports no conflicts of interest.

**Funding information**

This work was supported by grants from the Swedish Research Council (55X-06240) and the Swedish Diabetes Association (DIA2014-071, DIA2015-027).

**References**

1. Langerhans P. Beiträge zur mikroskopischen Anatomie der Bauchspeicheldrüse Berlin: Gustav Lange; 1869.
2. Diamare V. Studii comparativi sulle isole di Langerhans del pancreas. Internat Monatsch Anat Physiol. 1899;16:155–209.
3. Lane MA. The cytological characters of the areas of Langerhans. Am J Anat. 1907;7:409–22.
4. Homans J. A study of experimental diabetes in the canine and its relation to human diabetes. J Med Res. 1915;33:1–53.
5. Banting FG, Best CH. The internal secretion of the pancreas. J Lab Clin Med. 1922;7:251–66.
6. Murlin JR, Clough HD, Gibbs CBF, Stokes AM. Aqueous extracts of pancreas I. Influence on the carbohydrate metabolism of depancreatized animals. J Biol Chem. 1923;56:253–96.
7. Kimball C, Murlin J. Aqueous extracts of pancreas III. Some precipitation reactions of insulin. J Biol Chem. 1923;58:337–46.
8. Sutherland EW, De Duve C. Origin and distribution of the hyperglycemic-glycogenolytic factor of the pancreas. J Biol Chem. 1948;175:663–74.
9. Hellerström C, Hellman B. Some aspects of silver impregnation of the islets of Langerhans in the rat. Acta Endocrinol (Copenh). 1960;35:518–32.
10. Hellerström C, Hellman B. Reactions of the two types of A cells in the islets of Langerhans after administration of glucagon. Acta Endocrinol (Copenh). 1962;41:116–22.
11. Hellerström C, Howell SL, Edwards JC, Andersson A. An investigation of glucagon biosynthesis in isolated pancreatic islets of guinea pigs. FEBS Lett. 1972;27:97–101.
12. Andersson A, Petersson B, Westman J, Edwards J, Lundqvist G, Hellerström C. Tissue culture of $\beta$-cell rich pancreatic islets isolated from guinea-pigs. J Cell Biol. 1973;57:241–7.
13. Bloom W. A new type of granular cell in the islets of Langerhans after administration of glucagon. Acta Endocrinol (Copenh). 1960;35:518–32.
14. Hellerström C, Hellman B. Inhibition of the in vitro secretion of insulin by an extract of pancreatic $\alpha$-cells. Endocrinology. 1969;84:1484–8.
15. Goldsmith PC, Rose JC, Arimura A, Ganong WF. Ultrastructural localization of somatostatin in pancreatic islets of the rat. Endocrinology. 1975;97:1061–4.
16. Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA. Pancreatic extracts in the treatment of diabetes melilitus. Can Med Assoc J. 1922;12:141–6.
17. Cryer PE. Minireview: glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology. 2012;153:1039–48.

18. Unger RH, Cherrington AD. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest. 2012;122:4–12.

19. Wang MY, Yan H, Shi Z, Evans MR, Yu X, Lee Y, et al. Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway. Proc Natl Acad Sci U S A. 2015;112:2503–8.

20. Steenberg VR, Jensen SM, Pedersen J, Madsen AN, Windelov JA, Holst B, et al. Acute disruption of glucagon secretion or action does not improve glucose tolerance in an insulin-deficient mouse model of diabetes. Diabetologia. 2016;59:363–70.

21. Gerich JE. Glucose counterregulation and its impact on diabetes mellitus. Diabetes. 1988;37:1608–17.

22. Thorens B. Brain glucose sensing and neural regulation of insulin and glucagon secretion. Diabetes Obes Metab. 2011;13(Suppl 1):S8–S2.

23. Thorens B. Neural regulation of pancreatic islet cell mass and function. Diabetes Obes Metab. 2014;16(Suppl 1):87–95.

24. Rodriguez-Diaz R, Dando R, Jacques-Silva MC, Fachado A, Molina J, Abduraleev MH, et al. Alpha cells secrete acetylcholine as a non-neuronal paracrine signal priming beta cell function in humans. Nat Med. 2011;17:878–92.

25. Ashcroft FM, Rorsman P. Electrophysiology of the pancreatic β-cell. Prog Biophys Mol Biol. 1989;54:87–143.

26. Tengholm A, Gylfe E. Oscillatory control of insulin secretion. Mol Cell Endocrinol. 2009;297:58–72.

27. Gylfe E, Tengholm A. Neurotransmitter control of islet hormone pulsatility. Diabetes Obes Metab. 2014;16(Suppl 1):102–10.

28. Barg S, Galvanovskis J, Gromada J, Franklin I, Wollheim CB. AMP-activated protein kinase regulates glucagon secretion by high glucose concentrations. Diabetes. 2006;55:2318–23.

29. Huang YC, Rupnik MS, Karimian N, Herrera PL, Gilon P, Feng ZP, et al. In situ electrophysiological examination of pancreatic islets in the streptozotocin-induced diabetes model, revealing the cellular basis of glucagon hypersecretion. Diabetes. 2013;62:519–30.

30. Rorsman P, Braun M, Zhang Q. Regulation of calcium in pancreatic A-cells – unexposed and unexposed β-cells of the endocrine pancreas: the α-cells within intact pancreas. PLoS One. 2012;7:e47084.

31. Cabrera O, Jacques-Silva MC, Speier S, Yang SN, Kohler M, Fachado A, et al. Glutamate is a positive autocrine signal for glucagon release. Cell Metab. 2008;7:545–54.

32. Ostenson CG. Regulation of glucagon release: effects of insulin on the pancreatic Aβ-cell of the guinea pig. Diabetologia. 1979;17:325–30.

33. Elliott AD, Ustione A, Piston DW. Somatostatin and insulin mediate glucose-inhibited glucagon secretion in the pancreatic α-cell by lowering cAMP. Am J Physiol Endocrinol Metab. 2015;308:E130–43.

34. Franklin I, Gromada J, Gjinovic A, Theander S, Wollheim CB. β-Cell secretory products activate α-cell ATP-dependent potassium channels to inhibit glucagon release. Diabetes. 2005;54:1808–15.

35. Xu E, Kumar M, Zhang Y, Ju W, Obata T, Zhang N, et al. Intra-islet insulin suppresses glucagon release via GABA-GABAA receptor system. Cell Metab. 2006;3:47–58.

36. Ishihara H, Maechler P, Gjinovic A, Herrera PL, Wollheim CB. Islet β-cell secretion determines glucagon release from neighbouring α-cells. Nat Cell Biol. 2003;5:330–5.

37. Zhou H, Zhang T, Harmon JS, Bryan J, Robertson RP. Zinc, not insulin, regulates the rat α-cell response to hypoglycemia in vivo. Diabetes. 2007;56:1107–12.

38. Sluca M, Harmon JS, Oseid EA, Bryan J, Robertson RP. ATP-sensitive K+- channel mediates the zinc switch-off signal for glucagon response during glucose deprivation. Diabetes. 2010;59:128–34.

39. Tuder E, Filipetti E, Carneiro EM, Quesada I. Inhibition of Ca2+ signaling and glucagon secretion in mouse pancreatic α-cells by extracellular ATP and purinergic receptors. Am J Physiol Endocrinol Metab. 2008;294:E952–60.

40. Vieira E, Salehi A, Gylfe E. Glucose inhibits glucagon secretion by a direct effect on mouse pancreatic α-cells. Diabetologia. 2007;50:370–9.

41. Walker JN, Ramracheya R, Zhang Q, Johnson PR, Braun M, Rorsman P. Regulation of glucagon secretion by glucose: paracrine, intrinsic or both? Diabetes Obes Metab. 2011;13(Suppl 1):95–105.

42. Cabrera O, Jacques-Silva MC, Speier S, Yang SN, Kohler M, Fachado A, et al. Glutamate is a positive autocrine signal for glucagon release. Cell Metab. 2008;7:545–54.

43. Ostenson CG. Regulation of glucagon release: effects of insulin on the pancreatic Aβ-cell of the guinea pig. Diabetologia. 1979;17:325–30.

44. Elliott AD, Ustione A, Piston DW. Somatostatin and insulin mediate glucose-inhibited glucagon secretion in the pancreatic α-cell by lowering cAMP. Am J Physiol Endocrinol Metab. 2015;308:E130–43.
60. Bergsten P, Grapengiesser E, Gylfe E, Tengholm A, Hellman B. Synchronous oscillations of cytoplasmic Ca\(^{2+}\) and insulin release in glucose-stimulated pancreatic islets. J Biol Chem. 1994;269:8749–53.

61. Chapal J, Loubatieres-Mariani MM, Petit P, Roye M. Evidence for an A2-subtype adenosine receptor on pancreatic glucagon secreting cells. Br J Pharmacol. 1985;86:565–9.

62. Petit P, Loubatieres-Mariani MM, Keppens S, Sheehan MJ. Purinergic receptors and metabolic function. Drug Dev Res. 1996;39:413–25.

63. Grapengiesser E, Dansk H, Hellman B. Pulses of external ATP aid to the synchronization of pancreatic β-cells by generating premature Ca\(^{2+}\) oscillations. Biochem Pharmacol. 2004;68:667–74.

64. Gylfe E, Grapengiesser E, Dansk H, Hellman B. The neurotransmitter ATP triggers Ca\(^{2+}\) responses promoting coordination of pancreatic islet oscillations. Pancreas. 2012;41:258–63.

65. Cheng-Xue R, Gómez-Ruiz A, Antoine N, Noël LA, Chae HY, Rivier MA, et al. Tolbutamide controls glucagon release from mouse islets differently than glucose: involvement of K\(_{ATP}\) channels from both α- and β-cells. Diabetes. 2013;62:1612–22.

66. Starke A, Imanura T, Unger RH. Relationship of glucagon suppression by insulin and somatostatin to the ambient glucose concentration. J Clin Invest. 1987;79:20–4.

67. Klaff LJ, Taborsky GJ Jr. Pancreatic somatostatin is a mediator of glucagon inhibition by hyperglycemia. Diabetes. 1987;36:592–6.

68. Schuit FC, Derde MP, Pipeleers DG. Sensitivity of rat pancreatic A and B cells to somatostatin. Diabetologia. 1989;32:207–12.

69. Kumar U, Sasi R, Suresh S, Patel A, Thangaraju M, Metrakos P, et al. Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes. 1999;48:77–85.

70. Strowksi MZ, Parmar RM, Blake AD, Schaeffer JM. Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology. 2000;141:111–17.

71. Ludvigsen E, Carlsson C, Janson ET, Sandler S, Stridsberg M. Somatostatin receptor 1-5; expression profiles during rat development. Ups J Med Sci. 2015;120:157–68.

72. Orić L, Unger RH. Functional subdivision of islets of Langerhans and possible role of D cells. Lancet. 1975;2:1243–7.

73. Gromada J, Hay M, Buschard K, Salehi A, Rorsman P. Somatostatin inhibits exocytosis in rat pancreatic a-cells by G\(_\text{q}\)-dependent activation of calcineurin and depriming of secretory granules. J Physiol. 2001;535:519–32.

74. Göpel S, Zhang Q, Eliasson L, Ma XS, Galvanovskis J, Kanno T, et al. Capacitance measurements of exocytosis in mouse pancreatic α-, β- and δ-cells within intact islets of Langerhans. J Physiol. 2004;556:711–26.

75. Ipp E, Dobbs RE, Arimura A, Vale W, Harris U, Unger RH. Release of immunoreactive somatostatin from the pancreas in response to glucose, amino acids, pancreatic-cholecystokinin and tolbutamide. J Clin Invest. 1977;60:760–5.

76. Olsen HL, Theander S, Bovkist K, Buschard K, Wollheim CB, Gromada J. Glucose stimulates glucagon release in single rat α-cells by mechanisms that mirror the stimulus-secretion coupling in β-cells. Endocrinology. 2005;146:4861–70.

77. Le Marchand SJ, Piston DW. Glucose suppression of glucagon secretion: metabolic and calcium responses from α-cells in intact mouse pancreatic islets. J Biol Chem. 2010;8:285:14389–98.

78. Hutchens T, Piston DW. EphA4 receptor forward signaling inhibits glucagon secretion from α-cells. Diabetes. 2015;63:839–51.

79. Miao H, Wang B. EphA receptor signaling—complexity and emerging themes. Semin Cell Dev Biol. 2012;23:16–25.

80. Konstantinova I, Nikolova G, Ohara-Imaizumi M, Meda P, Kucera T, Zarbalis K, et al. EphA-Ephrin-A-mediated β cell communication regulates insulin secretion from pancreatic islets. Cell. 2007;129:359–70.

81. Liu YJ, Vieira E, Gylfe E. A store-operated mechanism determines the activity of the electrically excitable glucagon-secreting pancreatic α-cell. Cell Calcium. 2004;35:357–65.

82. Haumaitre C, Lenoir O, Scharfmann R. Directing cell differentiation with small-molecule histone deacetylase inhibitors: the example of promoting pancreatic endocrine cells. Cell Cycle. 2009;8:536–44.

83. De Vos A, Heimberg H, Quartier E, Huypens P, Bouwens L, Pipeleers D, et al. Human and rat beta cells differ in glucagon transport but not in glucokinin gene expression. J Clin Invest. 1995;96:2489–95.

84. Heimberg H, De Vos A, Pipeleers DG, Thorens B, Schuit FC. Differences in glucose transporter gene expression between rat pancreatic α- and β-cells are correlated to differences in glucose transport but not in glucose utilization. J Biol Chem. 1995;270:8971–5.

85. Heimberg H, De Vos A, Moens K, Quartier E, Bouwens L, Pipeleers D, et al. The glucose sensor protein glucokinase is expressed in glucagon-producing α-cells. Proc Natl Acad Sci U S A. 1996;93:7036–41.

86. Sweet IR, Matschinsky FM. Mathematical model of α-cell glucose metabolism and insulin release. I. Glucokinase as glucosensor hypothesis. Am J Physiol. 1995;268:E775–88.

87. Detrym P, Dejonghe S, Ling Z, Pipeleers D, Schuit F, Henquin JC. The changes in adenine nucleotides measured in glucose-stimulated rodent islets occur in β cells but not in α cells and are also observed in human islets. J Biol Chem. 1998;273:33905–8.

88. Schuit F, De Vos A, Farfari S, Moens K, Pipeleers D, Brun T, et al. Metabolic fate of glucose in purified islet cells. Glucose-regulated anaplerosis in β-cells. J Biol Chem. 1997;272:18572–9.

89. Ravier MA, Rutter GA. Glucose or insulin, but not zinc ions, inhibit glucagon secretion from mouse pancreatic α-cells. Diabetes. 2005;54:1789–97.

90. Quesada I, Todoralva MG, Soria B. Different metabolic responses in α-, β-, and δ-cells of the islet of Langerhans monitored by redox confocal microscopy. Biophys J. 2006;90:2641–50.

91. Quoix N, Cheng-Xue R, Mattart L, Zeinoun Z, Guitot Y, Beauvois MC, et al. Glucose and pharmacological modulators of ATP-sensitive K⁺ channels control [Ca\(^{2+}\)]\(_{\text{cyt}}\), by different mechanisms in isolated mouse α-cells. Diabetes. 2009;58:412–21.

92. MacDonald PE, De Marinis YZ, Ramracheya R, Salehi A, Ma X, Johnson PR, et al. A K\(_{\text{ATP}}\) channel-dependent pathway within α-cells regulates glucagon release from both rodent and human islets of Langerhans. PLoS Biol. 2007;5:e143.

93. Zhang Q, Ramracheya R, Lahmann C, Tarasov A, Bengtsson M, Braha O, et al. Role of K\(_{\text{ATP}}\) channels in glucagon-regulated glucagon secretion and impaired counterregulation in type 2 diabetes. Cell Metab. 2013;18:871–82.

94. Vieira E, Liu YJ, Gylfe E. Involvement of α2- and β2-adrenoceptors in adrenaline stimulation of the glucagon-secretory mouse α-cell. Naunyn Schmiedebergs Arch Pharmacol. 2004;369:179–83.

95. De Marinis YZ, Salehi A, Ward CE, Zhang Q, Abdulkader F, Bengtsson M, et al. GLP-1 inhibits and adrenal stimuli regulates glucagon release from the glucagon producing α-cell. Biochem Pharmacol. 2004;69:927–33.

96. Ramracheya R, Ward C, Shigeto M, Walker JN, Amisten S, Zhang Q, et al. Membrane potential-dependent inactivation of voltage-gated ion channels in α-cells inhibits glucagon secretory from mouse islets. Diabetes. 2010;59:2198–208.

97. Wang JL, McDaniel ML. Secretagogue-induced oscillations of cytoplasmic Ca\(^{2+}\) in single β and α-cells obtained from pancreatic islets by fluorescence-activated cell sorting. Biochem Biophys Res Commun. 1990;166:813–18.

98. Berts A, Ball A, Gylfe E, Hellman B. Suppression of Ca\(^{2+}\) oscillations in glucagon-producing γ-cells by insulin/glucagon and amino acids. Biochim Biophys Acta. 1996;1310:212–16.

99. Göpel SO, Kanno T, Barq S, Weng XF, Gromada J, Rorsman P. Regulation of glucagon secretion in mouse α-cells by K\(_{\text{ATP}}\) channels and inactivation of TTX-sensitive Na⁺ channels. J Physiol. 2000;528:509–20.

100. Gromada J, Ma X, Hoy M, Bovkist K, Salehi A, Berggren PO, et al. ATP-sensitive K⁺ channel-dependent regulation of glucagon
release and electrical activity by glucose in wild-type and SUR1−/− mouse α-cells. Diabetes. 2004;53:5181–9.

101. Linfoord B, Salehi A, Vergari E, Zhang Q, Rorsman P. Glucagon secretion from pancreatic α-cells. Ups J Med Sci. 2016;121:(In this issue).

102. Shiot A, Rocheleau JV, Shiot M, Piston DW, Magnuson MA. Impaired glucagon secretory responses in mice lacking the type 1 sulfonylurea receptor. Am J Physiol Endocrinol Metab. 2005;289:E570–7.

103. Miki T, Liss B, Minami K, Shiuchi T, Saraya A, Kashima Y, et al. Characterisation of sulphonylurea and ATP-regulated K⁺ channels in the hypothalamus are essential for the maintenance of glucagon homeostasis. Nat Neurosci. 2001;4:507–12.

104. Muñoz A, Hu M, Hussain K, Bryan J, Aguilar-Bryan L, Rajan AS. Regulation of glucagon secretion at low glucose concentrations: evidence for adenosine triphosphate-sensitive potassium channel involvement. Endocrinology. 2005;146:5514–21.

105. Bokvist K, Olsen HL, Hoy M, Gottfredsen CF, Holmes WF, Buschard K, et al. Characterisation of sulphonylurea and ATP-regulated K⁺ channels in rat pancreatic α-cells. Pflügers Arch. 1999;438:428–36.

106. Quesada I, Nadal A, Soria B. Different effects of tolbutamide and diazoxide in α, β-, and δ-cells within intact islets of Langerhans. Diabetes. 1999;48:2390–7.

107. Allister EM, Robson-Doucette CA, Prentice KJ, Hardy AB, Sultan S, Gaisano HY, et al. UCP2 regulates the glucagon response to fast- ing and starvation. Diabetes. 2013;62:1623–33.

108. Manning Fox JE, Gyulkhandanyan AV, Satin LS, Wheeler MB. Oscillatory membrane potential response to glucose in islet β-cells: a comparison of islet-cell electrical activity in mouse and rat. Endocrinology. 2006;147:4655–63.

109. Hjortoe GM, Hagel GM, Terry BR, Thastrup O, Arkhammar PO. Functional identification and monitoring of individual α and β cells in cultured mouse islets of Langerhans. Acta Diabetol. 2004;41:185–93.

110. Lieberman EM, Pascarella J, Brunder D, Hargittai PT. Effect of extracellular potassium on ouabain-sensitive consumption of high-energy phosphate by crayfish giant axons: a study of the energy requirement for transport in the steady state. J Neurochem. 1990;53:155–64.

111. Quoix N, Cheng-Xue R, Guiot Y, Herrera PL, Henquin JC, Gilon P. The GluCre-Rosa26EYFP mouse: a new model for easy identification of living pancreatic α-cells. FEBS Lett. 2007;581:4235–40.

112. Li J, Shuai HY, Gyfle E, Tengholm A. Oscillations of sub-membrane ATP in glucose-stimulated beta cells depend on negative feedback from Ca²⁺. Diabetologia. 2013;56:1577–86.

113. Chow RH, Lund PE, Löser S, Panten U, Gyfle E. Coincidence of early glucose-induced depolarization with lowering of cytoplasmic Ca²⁺ in mouse pancreatic β-cells. J Physiol. 1995;485:607–17.

114. Gyfle E. Glucose-induced early changes in cytoplasmic calcium of pancreatic β-cells studied with time-sharing dual-wavelength fluorometry. J Biol Chem. 1988;263:5044–8.

115. Westerlund J, Gyfle E, Bergsten P. Pulsatile insulin release from pancreatic islets with non-oscillatory elevation of cytoplasmic Ca²⁺. J Clin Invest. 1997;100:2547–51.

116. Johansson H, Gyfle E, Hellman B. Cyclic AMP raises cytoplasmic calcium in pancreatic β-cells by mobilizing calcium incorporated in response to glucose. Cell Calcium. 1989;10:205–11.

117. Liu YJ, Gyfle E. Store-operated Ca²⁺ entry in insulin-releasing pancreatic β-cells. Cell Calcium. 1997;22:277–86.

118. Dyachok O, Gyfle E. Store-operated influx of Ca²⁺ in the pancreatic β-cells exhibits graded dependence on the filling of the endoplasmatic reticulum. J Cell Sci. 2001;114:2719–86.

119. Gyfle E. Carbachol induces sustained glucose-dependent oscillations of cytoplasmic Ca²⁺ in hyperpolarized pancreatic β cells. Pflügers Arch. 1991;419:639–43.

120. Tengholm A, Hellman B, Gyfle E. Glucose regulation of free Ca²⁺ in the endoplasmatic reticulum of mouse pancreatic beta cells. J Biol Chem. 1999;274:36883–90.

121. Ravier MA, Daro D, Roma LP, Jonas JC, Cheng-Xue R, Schult FC, et al. Mechanisms of control of the free Ca²⁺ concentration in the endoplasmatic reticulum of mouse pancreatic β-cells: interplay with cell metabolism and [Ca²⁺]; and role of SERCA2b and SERCA3. Diabetes. 2011;60:2533–45.

122. Tian G, Tepikin AV, Tengholm A, Gyfle E. cAMP induces stromal interaction molecule 1 (STIM1) puncta but neither Orai1 protein clustering nor store-operated Ca²⁺ entry (SOCE) in islet cells. J Biol Chem. 2012;287:9862–72.

123. Bode HP, Weber S, Fehmann HC, Göke B. A nutrient-regulated cytosolic calcium oscillator in endocrine pancreatic glucagon-secreting cells. Pflügers Arch. 1999;437:324–34.

124. Lüger P. Electrogenic ion pumps. Sunderland, MA: Sinauer Associates Inc.; 1991.

125. Davies SL, Brown PD, Best L. Glucose-induced swelling in rat pancreatic α-cells. Mol Cell Endocrinol. 2007;264:61–7.

126. Boom A, Lybaert P, Pollet JF, Jacobs P, Jijakli H, Golstein PE, et al. Expression and localization of cystic fibrosis transmembrane conductance regulator in the rat endocrine pancreas. Endocrine. 2007;32:197–205.

127. Best L, Brown PD, Sener A, Malaisse WJ. Electrical activity in pancreatic islet cells: the VRAC hypothesis. Islets. 2010;2:59–64.

128. Sun G, da Silva Xavier G, Gorman T, Priest C, Solomou A, Hodson DJ, et al. LKB1 and AMPKζa and role of SERCA2b and SERCA3. Diabetes. 2015;64:61–7.

129. Watts M, Sherman A. Modeling the pancreatic α-cell: dual mechanisms of glucose suppression of glucagon secretion. Biophys J. 2014;106:741–51.